Literature DB >> 7656013

Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor.

N Borkakoti1, F K Winkler, D H Williams, A D'Arcy, M J Broadhurst, P A Brown, W H Johnson, E J Murray.   

Abstract

In rheumatoid and osteoarthritis, degradation of articular cartilage is mediated by the matrix metalloproteinases collagenase, stromelysin and gelatinase. The key event in this process is the cleavage of triple helical collagen by collagenase. We have determined the crystal structure of the catalytic domain of human recombinant fibroblast collagenase complexed with a synthetic inhibitor at 2.2 A resolution. The protein fold is similar to the amino termini of the zinc endopeptidases astacin thermolysin and elastase despite a lack of primary sequence homology. The conformation of the bound inhibitor provides a molecular basis for the design of inhibitors of collagenase and other matrix metalloproteinases. Such inhibitors should be useful in the treatment of a variety of diseases including arthritis and cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7656013     DOI: 10.1038/nsb0294-106

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  28 in total

Review 1.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

2.  Probing the role of divalent metal ions in a bacterial psychrophilic metalloprotease: binding studies of an enzyme in the crystalline state by x-ray crystallography.

Authors:  Stephanie Ravaud; Patrice Gouet; Richard Haser; Nushin Aghajari
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

4.  Binary image representation of a ligand binding site: its application to efficient sampling of a conformational ensemble.

Authors:  Edon Sung; Sangsoo Kim; Whanchul Shin
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

5.  Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.

Authors:  B C Finzel; E T Baldwin; G L Bryant; G F Hess; J W Wilks; C M Trepod; J E Mott; V P Marshall; G L Petzold; R A Poorman; T J O'Sullivan; H J Schostarez; M A Mitchell
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

6.  Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data.

Authors:  H Brandstetter; R A Engh; E G Von Roedern; L Moroder; R Huber; W Bode; F Grams
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

7.  Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X-ray crystallography.

Authors:  P R Gooley; J F O'Connell; A I Marcy; G C Cuca; M G Axel; C G Caldwell; W K Hagmann; J W Becker
Journal:  J Biomol NMR       Date:  1996-01       Impact factor: 2.835

Review 8.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

9.  Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP.

Authors:  Yoshifumi Itoh; Noriko Ito; Hideaki Nagase; Richard D Evans; Sarah A Bird; Motoharu Seiki
Journal:  Mol Biol Cell       Date:  2006-10-18       Impact factor: 4.138

10.  Solution structures of stromelysin complexed to thiadiazole inhibitors.

Authors:  B J Stockman; D J Waldon; J A Gates; T A Scahill; D A Kloosterman; S A Mizsak; E J Jacobsen; K L Belonga; M A Mitchell; B Mao; J D Petke; L Goodman; E A Powers; S R Ledbetter; P S Kaytes; G Vogeli; V P Marshall; G L Petzold; R A Poorman
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.